| 1 |
35113224 | Topical corticosteroid therapy for facial acneiform eruption due to EGFR inhibitors in metastatic colorectal cancer patients: a randomized controlled trial comparing starting with a very strong or a weak topical corticosteroid (FAEISS study, NCCH1512, colorectal part). | 2022 May |
2 |
| 2 |
35352492 | Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis. | 2022 Mar 29 |
1 |
| 3 |
34362003 | The Impact of Long-Term Antibiotic Therapy of Cutaneous Adverse Reactions to EGFR Inhibitors in Colorectal Cancer Patients. | 2021 Jul 21 |
1 |
| 4 |
33096790 | De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma. | 2020 Oct 21 |
1 |
| 5 |
28003335 | The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism. | 2017 Feb |
1 |
| 6 |
20820817 | Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). | 2011 Oct |
2 |
| 7 |
20428186 | Amphiregulin carboxy-terminal domain is required for autocrine keratinocyte growth. | 2010 Aug |
1 |
| 8 |
18543329 | Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). | 2008 Aug 15 |
1 |
| 9 |
17234777 | A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. | 2007 Jan 15 |
2 |
| 10 |
15115657 | Epstein-Barr virus latent membrane protein 1 modulates epidermal growth factor receptor promoter activity in a nuclear factor kappa B-dependent manner. | 2004 Jul |
1 |
| 11 |
15177893 | Nuclear factor kappa B (NFkappaB) dependent modulation of Epstein-Barr virus latent membrane protein 1 (LMP1) in epidermal growth factor receptor (EGFR) promoter activity. | 2004 Aug |
1 |
| 12 |
19877917 | Studies on engineered autocrine systems: requirements for ligand release from cells producing an artificial growth factor. | 1995 Spring |
2 |